The Prognostic Value of the Circulating Tumor Cell-Based Four mRNA Scoring System: A New Non-Invasive Setting for the Management of Bladder Cancer.
TRPM4
bladder cancer
circulating tumor cells
mRNA scoring system
recurrence
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Jun 2022
25 Jun 2022
Historique:
received:
19
05
2022
revised:
15
06
2022
accepted:
22
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
10
7
2022
Statut:
epublish
Résumé
Bladder cancer (BC) is one of the most expensive lifetime cancers to treat because of the high recurrence rate, repeated surgeries, and long-term cystoscopy monitoring and treatment. The lack of an accurate classification system predicting the risk of recurrence or progression leads to the search for new biomarkers and strategies. Our pilot study aimed to identify a prognostic gene signature in circulating tumor cells (CTCs) isolated by ScreenCell devices from muscle invasive and non-muscle invasive BC patients. Through the PubMed database and Cancer Genome Atlas dataset, a panel of 15 genes modulated in BC with respect to normal tissues was selected. Their expression was evaluated in CTCs and thanks to the univariate and multivariate Cox regression analysis, EGFR, TRPM4, TWIST1, and ZEB1 were recognized as prognostic biomarkers. Thereafter, by using the risk score model, we demonstrated that this 4-gene signature significantly grouped patients into high- and low-risk in terms of recurrence free survival (HR = 2.704, 95% CI = 1.010−7.313, Log-rank p < 0.050). Overall, we identified a new prognostic signature that directly impacted the prediction of recurrence, improving the choice of the best treatment for BC patients.
Identifiants
pubmed: 35804889
pii: cancers14133118
doi: 10.3390/cancers14133118
pmc: PMC9264990
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondazione Umberto Veronesi
ID : Post-doctoral Fellowship 2018, 2019
Organisme : PRIN
ID : Progetti di ricerca di rilevante interesse nazionale- Bando 2017, Prot. 2017FS5SHL
Références
Adv Drug Deliv Rev. 2018 Feb 1;125:102-121
pubmed: 29355669
Oncol Lett. 2018 Apr;15(4):5193-5200
pubmed: 29552157
BMC Cancer. 2020 Dec 7;20(1):1203
pubmed: 33287735
Nat Rev Mol Cell Biol. 2009 Jan;10(1):75-82
pubmed: 19197334
Ann Surg Oncol. 2020 Apr;27(4):1272-1281
pubmed: 31832914
Cancers (Basel). 2021 Nov 28;13(23):
pubmed: 34885101
Hematol Oncol Clin North Am. 2021 Jun;35(3):457-468
pubmed: 33958145
Int J Mol Sci. 2020 Nov 27;21(23):
pubmed: 33261027
Clin Cancer Res. 2018 Apr 1;24(7):1586-1593
pubmed: 29367430
Anal Cell Pathol (Amst). 2018 Mar 7;2018:9718585
pubmed: 29707475
Cancer Cell Int. 2021 Apr 26;21(1):233
pubmed: 33902589
Anticancer Res. 2021 Aug;41(8):3741-3746
pubmed: 34281832
Biomolecules. 2021 Feb 05;11(2):
pubmed: 33562811
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Cancer Cell. 2016 Jul 11;30(1):27-42
pubmed: 27321955
Am J Physiol Cell Physiol. 2004 Dec;287(6):C1667-78
pubmed: 15329338
Int J Mol Sci. 2017 Jan 11;18(1):
pubmed: 28085051
Pharmacol Ther. 2014 Feb;141(2):209-21
pubmed: 24134902
Front Oncol. 2020 Feb 07;10:102
pubmed: 32117752
Urol Oncol. 2009 May-Jun;27(3):268-76
pubmed: 18440840
BJU Int. 2013 Jul;112(2):E51-8
pubmed: 23795798
Cancer Lett. 2022 Jan 1;524:91-102
pubmed: 34656690
Eur Urol. 2014 Aug;66(2):253-62
pubmed: 24472711
Eur Urol. 2020 Oct;78(4):533-537
pubmed: 32684305
Oncotarget. 2017 Feb 28;8(9):15815-15826
pubmed: 28178659
Ann Surg Oncol. 2022 May;29(5):2882-2894
pubmed: 35000083
Cancers (Basel). 2022 Jan 28;14(3):
pubmed: 35158942
J Cell Physiol. 2007 May;211(2):296-306
pubmed: 17295211
Nat Rev Urol. 2019 Jan;16(1):23-34
pubmed: 30323201
Urology. 2011 Oct;78(4):863-7
pubmed: 21813167
Med Sci (Basel). 2020 Mar 13;8(1):
pubmed: 32183076
Ann Oncol. 2010 Apr;21(4):729-733
pubmed: 19850639
Hum Pathol. 2007 Apr;38(4):598-606
pubmed: 17258791
Oncotarget. 2017 Jul 11;8(51):89228-89235
pubmed: 29179514
Front Oncol. 2019 Sep 10;9:874
pubmed: 31552188
Oncologist. 2019 May;24(5):612-616
pubmed: 30944184
Biochim Biophys Acta. 2014 Feb;1838(2):682-91
pubmed: 23886913
Urol Oncol. 2022 Feb;40(2):63.e9-63.e18
pubmed: 34330652
Trends Biochem Sci. 2005 Dec;30(12):688-97
pubmed: 16260143
Eur Urol. 2012 Apr;61(4):810-7
pubmed: 22277196
Pharmaceuticals (Basel). 2022 Jan 06;15(1):
pubmed: 35056131
Oncotarget. 2022 Jan 12;13:105-117
pubmed: 35035776
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Curr Urol Rep. 2016 Mar;17(3):21
pubmed: 26874533
J Urol. 2015 Jan;193(1):53-7
pubmed: 24996129
Anticancer Res. 2020 Aug;40(8):4299-4307
pubmed: 32727757
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
Curr Biol. 2014 Aug 18;24(16):1909-17
pubmed: 25127216
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Lab Invest. 2022 Feb;102(2):143-153
pubmed: 34697421
Theranostics. 2018 Jun 12;8(14):3722-3736
pubmed: 30083255
Oncotarget. 2017 Mar 21;8(12):20380-20393
pubmed: 28099910
Thorac Cancer. 2022 Jan;13(2):265-266
pubmed: 34873852
Int J Mol Sci. 2021 Dec 22;23(1):
pubmed: 35008529
Oncol Lett. 2016 Dec;12(6):5235-5239
pubmed: 28101241
Int J Cancer. 2014 Oct 15;135(8):1978-82
pubmed: 24599551
Eur Urol. 2019 Jan;75(1):18-22
pubmed: 30266310
Biomedicines. 2021 Oct 01;9(10):
pubmed: 34680485
Cancers (Basel). 2020 May 30;12(6):
pubmed: 32486251
Cancer Lett. 2006 Nov 8;243(1):109-19
pubmed: 16455193
BMC Cancer. 2011 Aug 04;11:336
pubmed: 21816094
Clin Cancer Res. 2014 Jun 15;20(12):3233-43
pubmed: 24714775
Nat Mater. 2016 Dec;15(12):1287-1296
pubmed: 27548707
Nature. 1980 Jan 10;283(5743):139-46
pubmed: 6985715
World J Urol. 2019 Jan;37(1):31-40
pubmed: 30259123
Signal Transduct Target Ther. 2021 Nov 22;6(1):404
pubmed: 34803167
Oncotarget. 2017 Jun 16;8(35):59527-59538
pubmed: 28938656